Cargando…

3CL(pro) inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials

Detalles Bibliográficos
Autor principal:	Sisay, Mekonnen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128271/ https://www.ncbi.nlm.nih.gov/pubmed/32247821 http://dx.doi.org/10.1016/j.phrs.2020.104779

Ejemplares similares

Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?
por: Sisay, Mekonnen
Publicado: (2020)

Future Treatment Options in Systemic Sclerosis—Potential Targets and Ongoing Clinical Trials
por: Bohdziewicz, Anna, et al.
Publicado: (2022)

A Review on Currently Available Potential Therapeutic Options for COVID-19
por: Ohadian Moghadam, Solmaz
Publicado: (2020)

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers
por: Sisay, Mekonnen, et al.
Publicado: (2017)

Bioresorbable Scaffolds: Current Evidence and Ongoing Clinical Trials
por: Bourantas, Christos V., et al.
Publicado: (2012)

In silico screening of potential compounds from begonia genus as 3CL protease (3Cl pro) SARS-CoV-2 inhibitors
por: Maulana, Saipul, et al.
Publicado: (2023)

Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) proteases
por: Jade, Dhananjay, et al.
Publicado: (2021)

Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease
por: Khanna, Dinesh, et al.
Publicado: (2019)

Advances in developing small molecule SARS 3CL(pro) inhibitors as potential remedy for corona virus infection
por: Konwar, Manashjyoti, et al.
Publicado: (2021)

An overview of potential inhibitors targeting non-structural proteins 3 (PL(pro) and Mac1) and 5 (3CL(pro)/M(pro)) of SARS-CoV-2
por: Yan, Fangfang, et al.
Publicado: (2021)

Potential therapeutic options for COVID-19: an update on current evidence
por: Niknam, Zahra, et al.
Publicado: (2022)

Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials
por: Gdowski, Andrew S., et al.
Publicado: (2017)

Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials
por: Sobhani, Navid, et al.
Publicado: (2022)

Overview of Ongoing Clinical Trials on Radioembolization
por: Fabritius, Matthias P., et al.
Publicado: (2022)

Treating mitochondrial disorders requires full exploitation of available therapeutic options
por: Finsterer, Josef, et al.
Publicado: (2017)

Severe refractory asthma: current treatment options and ongoing research
por: Menzella, Francesco, et al.
Publicado: (2018)

Potential Broad Spectrum Inhibitors of the Coronavirus 3CL(pro): A Virtual Screening and Structure-Based Drug Design Study
por: Berry, Michael, et al.
Publicado: (2015)

Prioritisation of Compounds for 3CL(pro) Inhibitor Development on SARS-CoV-2 Variants
por: Jukič, Marko, et al.
Publicado: (2021)

QSAR and molecular docking studies of isatin and indole derivatives as SARS 3CL(pro) inhibitors
por: Soleymani, Niousha, et al.
Publicado: (2023)

Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
por: Edessa, Dumessa, et al.
Publicado: (2017)

Endobariatric procedures for obesity: clinical indications and available options
por: Goyal, Hemant, et al.
Publicado: (2021)

The development of Coronavirus 3C-Like protease (3CL(pro)) inhibitors from 2010 to 2020
por: Liu, Yuzhi, et al.
Publicado: (2020)

Discovery of novel non-peptidic and non-covalent small-molecule 3CL(pro) inhibitors as potential candidate for COVID-19 treatment
por: Jiang, Zhidong, et al.
Publicado: (2023)

Development of Broad‐Spectrum Halomethyl Ketone Inhibitors Against Coronavirus Main Protease 3CL(pro)
por: Bacha, Usman, et al.
Publicado: (2008)

Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CL(pro) inhibitors
por: Nukoolkarn, Veena, et al.
Publicado: (2008)

Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

Ongoing Clinical Trials of the Pleiotropic Effects of Statins
por: Davignon, Jean, et al.
Publicado: (2005)

Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option
por: Qin, Shuqi, et al.
Publicado: (2021)

DFT and MD simulation investigation of favipiravir as an emerging antiviral option against viral protease (3CL(pro)) of SARS-CoV-2
por: Yadav, Pooja, et al.
Publicado: (2021)

Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PL(pro) and M(pro)/ 3CL(pro): molecular docking and simulation studies of three pertinent medicinal plant natural components
por: Verma, Devvret, et al.
Publicado: (2021)

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
por: Liu, Si-Yang, et al.
Publicado: (2017)

Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences
por: Fernandes, Amélia Carolina Lopes, et al.
Publicado: (2020)

Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CL(pro) inhibitors as potential candidate for COVID-19 treatment
por: Jiang, Zhidong, et al.
Publicado: (2023)

Availability, pricing and affordability of essential medicines in Eastern Ethiopia: a comprehensive analysis using WHO/HAI methodology
por: Sisay, Mekonnen, et al.
Publicado: (2021)

Aromatase inhibitors in men: effects and therapeutic options
por: de Ronde, Willem, et al.
Publicado: (2011)

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?
por: Chan, Wei Yen, et al.
Publicado: (2021)

Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats
por: Lee, Kim May, et al.
Publicado: (2021)

Therapeutic Options for the Management of Pompe Disease: Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management
por: Bolano-Diaz, Carla, et al.
Publicado: (2022)

New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors
por: Regnier, Thomas, et al.
Publicado: (2009)

Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro)
por: Du, Ruikun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i9d2pcd7nqvcc727umn2crn2b7